Cargando…
Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice
Recently, accumulating evidence has suggested that gut microbiota may be involved in the occurrence and development of ankylosing spondylitis (AS). It has been suggested that rifaximin have the ability to modulate the gut bacterial communities, prevent inflammatory response, and modulate gut barrier...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409347/ https://www.ncbi.nlm.nih.gov/pubmed/30886835 http://dx.doi.org/10.3389/fcimb.2019.00044 |
_version_ | 1783401946910031872 |
---|---|
author | Yang, Lianjun Liu, Bin Zheng, Junchi Huang, Jincheng Zhao, Qinghao Liu, Jinshi Su, Zhihai Wang, Min Cui, Zhifei Wang, Tingxuan Zhang, Weicong Li, Qingchu Lu, Hai |
author_facet | Yang, Lianjun Liu, Bin Zheng, Junchi Huang, Jincheng Zhao, Qinghao Liu, Jinshi Su, Zhihai Wang, Min Cui, Zhifei Wang, Tingxuan Zhang, Weicong Li, Qingchu Lu, Hai |
author_sort | Yang, Lianjun |
collection | PubMed |
description | Recently, accumulating evidence has suggested that gut microbiota may be involved in the occurrence and development of ankylosing spondylitis (AS). It has been suggested that rifaximin have the ability to modulate the gut bacterial communities, prevent inflammatory response, and modulate gut barrier function. The goal of this work is to evaluate the protective effects of rifaximin in fighting AS and to elucidate the potential underlying mechanism. Rifaximin were administered to the proteoglycan (PG)-induced AS mice for 4 consecutive weeks. The disease severity was measured with the clinical and histological of arthritis and spondylitis. Intestinal histopathological, pro-inflammatory cytokine levels and the intestinal mucosal barrier were evaluated. Then, western blot was performed to explore the toll-like receptor 4 (TLR-4) signal transducer and NF-κB expression. Stool samples were collected to analyze the differences in the gut microbiota via next-generation sequencing of 16S rDNA. We found that rifaximin significantly reduced the severity of AS and resulted in down-regulation of inflammatory factors, such as TNF-α, IL-6, IL-17A, and IL-23. Meanwhile, rifaximin prevented ileum histological alterations, restored intestinal barrier function and inhibited TLR-4/NF-κB signaling pathway activation. Rifaximin also changed the gut microbiota composition with increased Bacteroidetes/Firmicutes phylum ratio, as well as selectively promoting some probiotic populations, including Lactobacillales. Our results suggest that rifaximin suppressed progression of AS and regulated gut microbiota in AS mice. Rifaximin might be useful as a novel treatment for AS. |
format | Online Article Text |
id | pubmed-6409347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64093472019-03-18 Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice Yang, Lianjun Liu, Bin Zheng, Junchi Huang, Jincheng Zhao, Qinghao Liu, Jinshi Su, Zhihai Wang, Min Cui, Zhifei Wang, Tingxuan Zhang, Weicong Li, Qingchu Lu, Hai Front Cell Infect Microbiol Cellular and Infection Microbiology Recently, accumulating evidence has suggested that gut microbiota may be involved in the occurrence and development of ankylosing spondylitis (AS). It has been suggested that rifaximin have the ability to modulate the gut bacterial communities, prevent inflammatory response, and modulate gut barrier function. The goal of this work is to evaluate the protective effects of rifaximin in fighting AS and to elucidate the potential underlying mechanism. Rifaximin were administered to the proteoglycan (PG)-induced AS mice for 4 consecutive weeks. The disease severity was measured with the clinical and histological of arthritis and spondylitis. Intestinal histopathological, pro-inflammatory cytokine levels and the intestinal mucosal barrier were evaluated. Then, western blot was performed to explore the toll-like receptor 4 (TLR-4) signal transducer and NF-κB expression. Stool samples were collected to analyze the differences in the gut microbiota via next-generation sequencing of 16S rDNA. We found that rifaximin significantly reduced the severity of AS and resulted in down-regulation of inflammatory factors, such as TNF-α, IL-6, IL-17A, and IL-23. Meanwhile, rifaximin prevented ileum histological alterations, restored intestinal barrier function and inhibited TLR-4/NF-κB signaling pathway activation. Rifaximin also changed the gut microbiota composition with increased Bacteroidetes/Firmicutes phylum ratio, as well as selectively promoting some probiotic populations, including Lactobacillales. Our results suggest that rifaximin suppressed progression of AS and regulated gut microbiota in AS mice. Rifaximin might be useful as a novel treatment for AS. Frontiers Media S.A. 2019-03-04 /pmc/articles/PMC6409347/ /pubmed/30886835 http://dx.doi.org/10.3389/fcimb.2019.00044 Text en Copyright © 2019 Yang, Liu, Zheng, Huang, Zhao, Liu, Su, Wang, Cui, Wang, Zhang, Li and Lu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Yang, Lianjun Liu, Bin Zheng, Junchi Huang, Jincheng Zhao, Qinghao Liu, Jinshi Su, Zhihai Wang, Min Cui, Zhifei Wang, Tingxuan Zhang, Weicong Li, Qingchu Lu, Hai Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice |
title | Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice |
title_full | Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice |
title_fullStr | Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice |
title_full_unstemmed | Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice |
title_short | Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice |
title_sort | rifaximin alters intestinal microbiota and prevents progression of ankylosing spondylitis in mice |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409347/ https://www.ncbi.nlm.nih.gov/pubmed/30886835 http://dx.doi.org/10.3389/fcimb.2019.00044 |
work_keys_str_mv | AT yanglianjun rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT liubin rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT zhengjunchi rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT huangjincheng rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT zhaoqinghao rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT liujinshi rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT suzhihai rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT wangmin rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT cuizhifei rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT wangtingxuan rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT zhangweicong rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT liqingchu rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice AT luhai rifaximinaltersintestinalmicrobiotaandpreventsprogressionofankylosingspondylitisinmice |